Up in smoke? Vaping on the edge of banishment

Industry Insight
Jul.13.2022

The U.S. Food and Drug Administration (FDA) has paused a ban on the sale of Juul Labs’ e-cigarettes, saying it requires an additional review of the company’s marketing application.

 

This pause follows a federal appeals court’s decision a few weeks ago to stay — i.e. temporarily freeze — the FDA’s ban, following an appeal from Juul requesting an emergency review of the FDA’s order.

 

But the once-thriving company isn’t out of the woods just yet: The FDA has only paused the ban for reevaluation. It has not rescinded it.

 

Juul has always been in the spotlight, in part because of its prominent placement atop the e-cigarette chain, but with the company facing a potential demise, it could be the first casualty, with the rest of the vaping industry in the government’s sights.

 

Dr. Zubair Karim, assistant professor in the Department of Interdisciplinary Health Sciences at Augusta University, was a researcher on a study that looked at Juul e-cigarettes and how they elevate the risk of thrombosis and other complications in patients.

 

Up in smoke? Vaping on the edge of banishment

 

“Thrombosis is the formation of a blood clot, either partial or complete blockage, within blood vessels, whether venous or arterial, limiting the natural flow of blood,” Karim said.

 

“There are several complications depending on where the thrombosis is located. The most serious problems include stroke, heart attack and serious breathing problems, which is called pulmonary embolism. If the patients are not treated in a timely manner, it will lead to life-threatening conditions. However, progression of the disease can be prevented by following changes in our lifestyle such as increasing physical activity, quitting smoking, losing weight, eating a balanced diet, quitting junk food and managing other health conditions.”

 

With the ban on Juul products, could this result in a ban on other companies’ e-cigarette products as well, or was there something specifically about Juul that caused their ban?

 

“This is the first steps toward the banning of the e-cigarette, i.e., Juul, where the FDA took a significant and bold step,” Karim said.

 

“Gradually, this will open the path for banning of the other e-cigarette products. There are no differences in the Juul and other products, but Juul became more popular in our young generation. Many local and state jurisdictions have recently begun enacting laws that prohibit e-cigarette usage, although some state laws with comprehensive smoke-free laws will still allow for vaping to be permitted in bars and restaurants while prohibiting e-cigarettes in other indoor places.”

 

For years, e-cigarettes and vaping devices were seen as a “safer” alternative to traditional cigarettes, but with flavors and packaging that has attracted children to the fad, efforts have been renewed to look into the possible side effects.

 

“Both smoking and vaping have similar side effects and cause serious health risks in the long run. Scientists do not fully understand the long-term health effects of electronic cigarettes, yet science indicates that they are not a safe alternative to smoking,” said Karim.

 

“In the last several years it has been observed that vaping is growing in popularity among teenagers. Moreover, e-cigarettes contain a large dose of nicotine, a substance known to slow the development of brains in fetuses, children and teens. Furthermore, vaping involves breathing in aerosol that contains several chemicals, including nicotine and flavoring through an e-cigarette or other devices. Also, the liquid present in the e-cigarettes which creates the vapor is dangerous to adults and children if they swallow, inhale, or get it on the skin.

 

Nonetheless, vaping also delivers dangerous chemicals, including diacetyl, cancer-causing chemicals, heavy metals, volatile organic compounds, and such toxic chemicals that are not generated in traditional cigarettes. In summary, long-term vaping causes similar toxic impact to overall health compared to traditional cigarettes.”

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Bringing Tax and Insurance Into Nicotine Regulation: Insights From a Tobacco Harm-Reduction Report
Bringing Tax and Insurance Into Nicotine Regulation: Insights From a Tobacco Harm-Reduction Report
A smoke-free nicotine policy report argues that tobacco harm reduction should move beyond product bans and health warnings into tax policy, insurance pricing and risk-based regulation. While some projections remain open to debate, the report highlights a wider challenge: nicotine products, technologies and consumer behavior have changed sharply over the past decade, and regulatory systems may need new tools to better align tobacco control with harm-reduction goals.
Jun.08
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
CTT Pharmaceutical Holdings said it has signed a letter of intent with a U.S. company to conduct clinical trials and testing for several potential nicotine products using its patented oral thin-film technology.
Jun.18
2Firsts Interview | InterTabac 2026 Adapts to a More Complex Tobacco and Nicotine Market
2Firsts Interview | InterTabac 2026 Adapts to a More Complex Tobacco and Nicotine Market
As InterTabac 2026 approaches, Sabine Loos, Managing Director of Westfalenhallen Unternehmensgruppe, tells 2Firsts that global tobacco trade fairs are evolving beyond product display. With new nicotine categories, shifting regulation and more complex supply chains reshaping the industry, InterTabac is positioning itself as a platform for market insight, regulatory discussion and global business connection.
Special Report
Jul.02
Product | Vapsolo Launches Sixer 180K, Introducing a 6-in-1 Architecture for Disposable Vapes
Product | Vapsolo Launches Sixer 180K, Introducing a 6-in-1 Architecture for Disposable Vapes
Vapsolo has launched the Sixer 180K, a flagship disposable vape built around a 6-in-1 architecture featuring six independent e-liquid tanks and six dedicated mesh coils. Alongside a claimed up to 180,000 puffs, the new device reflects a broader shift in disposable vape development from increasing puff counts toward modular hardware design and multi-flavor user experience.
Jul.03
Nicotine Pouches Lead U.S. Tobacco Growth as Vape Sales Decline
Nicotine Pouches Lead U.S. Tobacco Growth as Vape Sales Decline
New convenience store industry data show nicotine pouches have become the primary growth driver in the tobacco category, with oral nicotine sales rising nearly 30% over the past year while vape sales declined.
Business
Jun.05
Trump’s Tobacco Investments and Industry Donations Draw Scrutiny as FDA Eases Vape and Nicotine Pouch Rules
Trump’s Tobacco Investments and Industry Donations Draw Scrutiny as FDA Eases Vape and Nicotine Pouch Rules
A report by KFF Health News says that as the Trump administration pursued a series of policies favorable to the nicotine and tobacco industry, President Donald Trump increased his holdings in tobacco companies while benefiting from substantial industry-linked political donations, prompting questions from public health advocates about potential conflicts of interest and regulatory direction.
Jun.12